NZ703829A - Acetaminophen injectable solution for spinal administration - Google Patents

Acetaminophen injectable solution for spinal administration

Info

Publication number
NZ703829A
NZ703829A NZ703829A NZ70382913A NZ703829A NZ 703829 A NZ703829 A NZ 703829A NZ 703829 A NZ703829 A NZ 703829A NZ 70382913 A NZ70382913 A NZ 70382913A NZ 703829 A NZ703829 A NZ 703829A
Authority
NZ
New Zealand
Prior art keywords
spinal administration
acetaminophen
acetaminophen injectable
injectable solution
spinal
Prior art date
Application number
NZ703829A
Other languages
English (en)
Inventor
Augusto Mitidieri
Elisabetta Donati
Nicola Caronzolo
Original Assignee
Sint Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ703829(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sint Sa filed Critical Sint Sa
Publication of NZ703829A publication Critical patent/NZ703829A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ703829A 2012-06-29 2013-06-27 Acetaminophen injectable solution for spinal administration NZ703829A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001154A ITMI20121154A1 (it) 2012-06-29 2012-06-29 Soluzione iniettabile di acetaminofene per la somministrazione spinale
PCT/IB2013/055277 WO2014002042A1 (en) 2012-06-29 2013-06-27 Injectable supersaturated acetaminophen solution for spinal administration

Publications (1)

Publication Number Publication Date
NZ703829A true NZ703829A (en) 2016-06-24

Family

ID=46690603

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ703829A NZ703829A (en) 2012-06-29 2013-06-27 Acetaminophen injectable solution for spinal administration

Country Status (44)

Country Link
US (2) US11344517B2 (enExample)
EP (1) EP2874602B1 (enExample)
JP (1) JP5876620B2 (enExample)
KR (1) KR102118227B1 (enExample)
CN (1) CN104487051B (enExample)
AP (1) AP2014008152A0 (enExample)
AR (1) AR091633A1 (enExample)
AU (1) AU2013282753B2 (enExample)
BR (1) BR112014032818B1 (enExample)
CA (1) CA2876801C (enExample)
CL (1) CL2014003536A1 (enExample)
CO (1) CO7240357A2 (enExample)
CR (1) CR20150036A (enExample)
CU (1) CU20140150A7 (enExample)
CY (1) CY1117691T1 (enExample)
DK (1) DK2874602T3 (enExample)
DO (1) DOP2014000302A (enExample)
EA (1) EA028909B1 (enExample)
EC (1) ECSP15000500A (enExample)
ES (1) ES2578012T3 (enExample)
GE (1) GEP201706689B (enExample)
HR (1) HRP20160706T1 (enExample)
HU (1) HUE029431T2 (enExample)
IL (1) IL236423A (enExample)
IT (1) ITMI20121154A1 (enExample)
MA (1) MA37811B1 (enExample)
MD (1) MD4537C1 (enExample)
ME (1) ME02431B (enExample)
MX (1) MX369264B (enExample)
MY (1) MY169251A (enExample)
NI (1) NI201400147A (enExample)
NZ (1) NZ703829A (enExample)
PE (1) PE20150331A1 (enExample)
PH (1) PH12015500178B1 (enExample)
PL (1) PL2874602T3 (enExample)
PT (1) PT2874602T (enExample)
RS (1) RS54844B1 (enExample)
SG (2) SG11201408479WA (enExample)
SI (1) SI2874602T1 (enExample)
SM (1) SMT201600248B (enExample)
TN (1) TN2014000526A1 (enExample)
UA (1) UA117101C2 (enExample)
WO (1) WO2014002042A1 (enExample)
ZA (1) ZA201409478B (enExample)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69427728T2 (de) * 1993-04-14 2002-05-08 Nippon Sanso Corp., Tokio/Tokyo Vorrichtung zur herabsetzung vom gelöstem sauerstoff
US6171298B1 (en) * 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
DE10112325A1 (de) * 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
US20050203175A1 (en) * 2001-12-18 2005-09-15 Ioulia Tseti Parenteral composition of paracetamol
FR2851164B1 (fr) * 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
DE102005037653A1 (de) * 2005-08-05 2007-02-15 Theraselect Gmbh Stabile, flüssige Formulierung von Paracetamol
RU2419421C2 (ru) * 2006-07-18 2011-05-27 Хенфарма Лабораторио С.Л. Инъецируемая жидкая композиция парацетамола
CN101015542A (zh) * 2007-02-13 2007-08-15 天津生机集团有限公司 家畜用复方对乙酰氨基酚注射液及其制备方法
MD3528G2 (ro) * 2007-09-28 2008-11-30 Сергей ШАНДРУ Metodă de anestezie spinală continuă la pacienţii în etate
JP5909750B2 (ja) * 2007-11-13 2016-04-27 マリンクロット アイピー 低用量静脈内アセトアミノフェン
WO2009098716A2 (en) 2008-01-17 2009-08-13 Aptuit Laurus Private Limited Stable pharmaceutical aqueous compositions
WO2009143558A1 (en) 2008-05-26 2009-12-03 Silphion Pty Limited Injectable formulations
EP2243477A1 (de) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
JP2013006770A (ja) 2009-10-09 2013-01-10 Ssp Co Ltd アセトアミノフェン含有経口液剤
PT2588097T (pt) * 2010-06-30 2021-05-25 Troikaa Pharmaceuticals Ltd Composições farmacêuticas que compreendem paracetamol e processo para preparar as mesmas

Also Published As

Publication number Publication date
AR091633A1 (es) 2015-02-18
EA201500065A1 (ru) 2015-10-30
MD20140138A2 (ro) 2015-06-30
ME02431B (me) 2016-09-20
US20150148379A1 (en) 2015-05-28
DOP2014000302A (es) 2015-03-15
EA028909B1 (ru) 2018-01-31
SMT201600248B (it) 2016-08-31
PH12015500178A1 (en) 2015-04-06
CU20140150A7 (es) 2015-10-27
CN104487051B (zh) 2017-12-12
CA2876801A1 (en) 2014-01-03
AU2013282753B2 (en) 2017-03-02
SI2874602T1 (sl) 2016-09-30
IL236423A0 (en) 2015-02-26
MD4537B1 (ro) 2017-12-31
US11344517B2 (en) 2022-05-31
PE20150331A1 (es) 2015-03-07
JP5876620B2 (ja) 2016-03-02
AU2013282753A1 (en) 2015-02-05
SG10201704482YA (en) 2017-07-28
US20160128955A1 (en) 2016-05-12
BR112014032818B1 (pt) 2022-06-14
EP2874602B1 (en) 2016-03-30
MD4537C1 (ro) 2018-07-31
MY169251A (en) 2019-03-19
UA117101C2 (uk) 2018-06-25
PH12015500178B1 (en) 2021-08-04
CR20150036A (es) 2015-03-13
MA37811B1 (fr) 2017-07-31
TN2014000526A1 (en) 2016-03-30
HUE029431T2 (en) 2017-03-28
PT2874602T (pt) 2016-07-13
ES2578012T3 (es) 2016-07-20
MA37811A1 (fr) 2016-10-31
CL2014003536A1 (es) 2015-05-08
KR102118227B1 (ko) 2020-06-03
MX2014015402A (es) 2015-06-17
EP2874602A1 (en) 2015-05-27
SG11201408479WA (en) 2015-01-29
IL236423A (en) 2017-07-31
GEP201706689B (en) 2017-06-26
RS54844B1 (sr) 2016-10-31
DK2874602T3 (en) 2016-07-04
ITMI20121154A1 (it) 2013-12-30
CY1117691T1 (el) 2017-05-17
PL2874602T3 (pl) 2016-10-31
AP2014008152A0 (en) 2014-12-31
CN104487051A (zh) 2015-04-01
ECSP15000500A (es) 2015-11-30
ZA201409478B (en) 2016-01-27
CO7240357A2 (es) 2015-04-17
HRP20160706T1 (hr) 2016-08-12
JP2015522004A (ja) 2015-08-03
KR20150027160A (ko) 2015-03-11
WO2014002042A1 (en) 2014-01-03
NI201400147A (es) 2015-04-13
MX369264B (es) 2019-11-04
BR112014032818A2 (pt) 2017-06-27
CA2876801C (en) 2020-11-03

Similar Documents

Publication Publication Date Title
TN2014000356A1 (en) Heterocyclyl compounds as mek inhibitors
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
IN2014DN09434A (enExample)
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MY188139A (en) Sodium channel modulators for the treatment of pain
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
EA201590697A1 (ru) Производные кетамина
NZ714684A (en) Stable oral solutions for combined api
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MY196979A (en) Method of treating disease by auricular anesthesia of cranial nerves
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
PH12015500178B1 (en) Injectable supersaturated acetaminophen solution for spinal administration
UA111785C2 (uk) Композиція для лікування бородавок та спосіб лікування бородавок
IN2013MU03613A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2018 BY CPA GLOBAL

Effective date: 20170512

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2019 BY CPA GLOBAL

Effective date: 20180510

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2020 BY CPA GLOBAL

Effective date: 20190516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2021 BY CPA GLOBAL

Effective date: 20200514

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JUN 2022 BY CPA GLOBAL

Effective date: 20210513

LAPS Patent lapsed